Developing therapeutics and medical devices for global healthcare markets remains a risky proposition. Having largely overcome the patent cliff era that resulted from an excess of me-too product development, the medical innovations now coming to market are remarkable and reflect the reaction of healthcare companies towards innovation a decade ago. L.E.K.’s Partner, Clay Heskett, explains how the challenges for the next generation of therapeutics and devices will be different again.

Related Insights